Claritin in Japan
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's Japanese subsidiary will launch RediTabs imminently, the firm announces. The product is "the first and only allergy product in Japan designed to orally disintegrate," Schering says. The Rx drug's indications mirror those for use in the U.S. The Japanese Ministry of health cleared Claritin for prescription status in 2002 (1"The Tan Sheet" July 15, 2002, In Brief)...
You may also be interested in...
Generic Claritin-D
Andrx receives tentative FDA approval July 9 for 24-hour loratadine/pseudoephedrine combination. Generics company is believed to be first to file an ANDA for equivalent to Schering-Plough's Claritin-D 24-Hour; Impax Labs was first to file for 12-hour formulation and has entered into contract manufacturing, supply agreement with Schering for OTC distribution (1"The Tan Sheet" July 1, 2002, p. 4). Andrx, Impax are defendants in Schering's ongoing patent litigation. Separately, Schering announces July 8 approval in Japan for Rx sale of Claritin 10 mg tablets...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.